Arvinas Inc (NASDAQ:ARVN) Given Average Rating of “Buy” by Brokerages

Shares of Arvinas Inc (NASDAQ:ARVN) have earned an average broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and two have given a strong buy recommendation to the company. Arvinas’ rating score has declined by 67% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Brokers have set a 1-year consensus target price of $27.00 for the company and are expecting that the company will post ($0.46) earnings per share for the current quarter, according to Zacks. Zacks has also given Arvinas an industry rank of 57 out of 256 based on the ratings given to its competitors.

ARVN has been the topic of several research analyst reports. Piper Jaffray Companies dropped their target price on shares of Apyx Medical to $7.00 and set an “overweight” rating on the stock in a report on Wednesday, May 8th. Evercore ISI assumed coverage on shares of Homology Medicines in a research report on Thursday, April 11th. They set an “outperform” rating and a $29.00 price objective for the company. Citigroup reduced their price objective on shares of Tremont Mortgage Trust from $9.50 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, June 5th. Finally, Zacks Investment Research cut shares of Home Bancshares from a “hold” rating to a “sell” rating in a research report on Friday, June 7th.

In related news, major shareholder Ventures Iii L.P. 5Am sold 190,000 shares of the stock in a transaction on Friday, June 7th. The stock was sold at an average price of $19.65, for a total value of $3,733,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 31.77% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Arvinas by 109.2% during the 4th quarter. BlackRock Inc. now owns 545,443 shares of the company’s stock valued at $7,009,000 after acquiring an additional 284,656 shares during the last quarter. Deutsche Bank AG purchased a new position in shares of Arvinas during the fourth quarter valued at approximately $135,000. Northern Trust Corp purchased a new position in shares of Arvinas during the fourth quarter valued at approximately $982,000. American International Group Inc. purchased a new position in shares of Arvinas during the fourth quarter valued at approximately $66,000. Finally, Spark Investment Management LLC boosted its position in shares of Arvinas by 91.9% during the first quarter. Spark Investment Management LLC now owns 35,500 shares of the company’s stock valued at $523,000 after purchasing an additional 17,000 shares in the last quarter. Institutional investors own 42.93% of the company’s stock.

Shares of ARVN stock traded down $1.22 during mid-day trading on Wednesday, reaching $23.88. The company’s stock had a trading volume of 4,414 shares, compared to its average volume of 307,061. Arvinas has a 1-year low of $10.19 and a 1-year high of $27.80. The company has a market capitalization of $804.60 million and a P/E ratio of -0.93. The company has a debt-to-equity ratio of 0.03, a quick ratio of 8.73 and a current ratio of 8.73. The firm’s 50-day moving average is $22.49.

Arvinas (NASDAQ:ARVN) last announced its earnings results on Wednesday, May 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.46). The firm had revenue of $4.02 million for the quarter, compared to analyst estimates of $3.50 million. On average, analysts forecast that Arvinas will post -1.86 EPS for the current fiscal year.

About Arvinas

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

Featured Story: Reverse Stock Split

Get a free copy of the Zacks research report on Arvinas (ARVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.